FierceBiotech ٢ يناير ٢٠٢٦ Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease
FierceBiotech ٢ يناير ٢٠٢٦ AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
FierceBiotech ٢ يناير ٢٠٢٦ Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout
FierceBiotech ٢ يناير ٢٠٢٦ Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
FierceBiotech ٣١ ديسمبر ٢٠٢٥ Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study
FierceBiotech ٣٠ ديسمبر ٢٠٢٥ Breast cancer tops list of most-studied diseases for 5th year in a row: report
FierceBiotech ٢٣ ديسمبر ٢٠٢٥ Edwards nets FDA approval for Sapien M3 transcatheter mitral valve replacement
FierceBiotech ٢٣ ديسمبر ٢٠٢٥ Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree
FierceBiotech ٢٣ ديسمبر ٢٠٢٥ Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate
FierceBiotech ٢٣ ديسمبر ٢٠٢٥ Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data
FierceBiotech ٢٣ ديسمبر ٢٠٢٥ Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
FierceBiotech ٢٢ ديسمبر ٢٠٢٥ BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement